Department of Research, Centre hospitalier du Rouvray, Sotteville-lès-Rouen, France.
Department of Genetics, Normandy Centre for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Rouen, France.
Transl Psychiatry. 2018 Dec 5;8(1):268. doi: 10.1038/s41398-018-0291-7.
This study aims at assessing the burden of rare (minor allele frequency < 1%) predicted damaging variants in the whole exome of 92 bipolar I disorder (BD) patients and 1051 controls of French ancestry. Patients exhibiting an extreme phenotype (earlier onset and family history of mood disorder) were preferentially included to increase the power to detect an association. A collapsing strategy was used to test the overall burden of rare variants in cases versus controls at the gene level. Only protein-truncating and predicted damaging missense variants were included in the analysis. Thirteen genes exhibited p values exceeding 10 and could be considered as potential risk factors for BD. Furthermore, the validity of the association was supported when the Exome Aggregation Consortium database non-Finnish European population was used as controls for eight of them. Their gene products are involved in various cerebral processes, some of which were previously implicated in BD and belong to pathways implicated in the therapeutic effect of lithium, the main mood stabilizer. However, exome-wide threshold for association study was not reached, emphasizing that larger samples are needed.
本研究旨在评估 92 名双相情感障碍 (BD) 患者和 1051 名法国血统对照者全外显子组中罕见(小等位基因频率 < 1%)预测有害变异的负担。为了提高检测关联的能力,优先纳入表现出极端表型(发病早和心境障碍家族史)的患者。使用崩溃策略在基因水平上测试病例与对照之间罕见变异的总体负担。仅纳入截断蛋白和预测有害错义变异的分析。有 13 个基因的 p 值超过 10,可被视为 BD 的潜在危险因素。此外,当将 Exome Aggregation Consortium 数据库的非芬兰欧洲人群作为其中 8 个基因的对照时,关联的有效性得到了支持。它们的基因产物涉及各种大脑过程,其中一些先前与 BD 有关,并且属于锂(主要的心境稳定剂)治疗效果所涉及的途径。然而,全外显子关联研究的阈值并未达到,这强调需要更大的样本量。